$RGNX

RGNX faces class action lawsuit alleging false statements about RGX-111 safety. FDA clinical hold imposed after trial participant developed tumor.

Pomerantz Law Firm files class action suit against $RGNX after FDA clinical hold on gene therapy candidates triggers 17.9% stock collapse. Investor deadline: April 14, 2026.

Pomerantz Law Firm filed class action suit against $AMC over alleged securities fraud involving APE preferred equity holders excluded from special dividend. Investors must act by April 20, 2026.

REGENXBIO faces class action lawsuit after FDA halted RGX-111 gene therapy trial due to CNS tumor, triggering 18% stock decline.

REGENXBIO ($RGNX) investors have until April 14, 2026 to join securities class action over allegedly misleading RGX-111 trial statements.

Investors in $REGENXBIO face class action lawsuit alleging false statements about RGX-111 gene therapy development and clinical trial results spanning 2022-2026.

Schall Law Firm seeks lead plaintiffs in class action against REGENXBIO for allegedly concealing negative efficacy and safety data on RGX-111 candidate drug.

REGENXBIO faces securities class action alleging false statements about RGX-111 gene therapy. Lead plaintiff deadline April 14, 2026.

Rosen Law Firm seeks lead plaintiffs in securities lawsuit against BlackRock TCP Capital ($TCPC) alleging false investment valuations and NAV misstatements, with April 6, 2026 deadline.

Securities lawsuit alleges REGENXBIO made misleading statements about RGX-111 gene therapy. Investors have until April 14, 2026 to file.

Law firm Bragar Eagel & Squire announces class actions against $PYPL and $RGNX over alleged false projections and concealed safety risks, following significant stock declines.

Rosen Law Firm urges Snowflake investors to join securities class action alleging the company made misleading statements while concealing material negative information, causing stock price losses.

REGENXBIO faces class action securities fraud lawsuit over allegedly concealed safety data for gene therapy RGX-111, triggered by CNS tumor discovery in clinical trial.

REGENXBIO ($RGNX) sued for alleged securities violations involving undisclosed adverse trial data on RGX-111 candidate after FDA clinical hold.

Schall Law Firm seeks $RGNX investors for securities fraud class action alleging false statements about RGX-111 candidate, following tumor discovery in trial participant.

Rosen Law Firm filed securities class action against $FBRT, alleging false statements on business prospects and dividend sustainability. Lead plaintiff deadline set for April 27, 2026.

Rosen Law Firm recruits lead plaintiffs for securities class action against REGENXBIO over alleged false statements regarding RGX-111 gene therapy trial data. Lead plaintiff deadline: April 14, 2026.

Rosen Law Firm recruits investors for securities class action against REGENXBIO over alleged RGX-111 gene therapy misstatements. Lead plaintiff deadline: April 14, 2026.

Rosen Law Firm files securities class action against Paysafe Limited, alleging false statements about business operations and financial performance. Investors must act before lead plaintiff deadline.

Securities lawsuit filed against $RGNX alleging misleading statements about RGX-111 gene therapy. Eligible investors must act before April 14, 2026 deadline.